Evidence map›Paper›PMID 37442307›Full record

ArticleAnnals of epidemiology2023

Alcohol use and the longitudinal HIV care continuum for people with HIV who enrolled in care between 2011 and 2019.

Catherine R Lesko, Jeanine S Gnang, Anthony T Fojo, Heidi E Hutton, Mary E McCaul, Joseph A Delaney, Edward R Cachay, Kenneth H Mayer, Heidi M Crane, D Scott Batey and 4 more

Open access · greenAbstract read
In one paragraph

Article in Annals of epidemiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 2 countries.

Catherine R LeskoDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. Electronic address: clesko2@jhu.edu.
Jeanine S GnangDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Anthony T FojoSchool of Medicine, Johns Hopkins University, Baltimore, MD.
Heidi E HuttonSchool of Medicine, Johns Hopkins University, Baltimore, MD.
Mary E McCaulSchool of Medicine, Johns Hopkins University, Baltimore, MD.
Joseph A DelaneyCollege of Pharmacy, University of Manitoba, Winnipeg, Canada; Department of Epidemiology, University of Washington, Seattle, WA.
Edward R CachayDepartment of Medicine, Division of Infectious Diseases, University of California San Diego, San Diego, CA.
Kenneth H MayerSchool of Medicine, Harvard University, Cambridge, MA.
Heidi M CraneDepartment of Medicine, School of Medicine, University of Washington, Seattle, WA.
D Scott BateySchool of Social Work, Tulane University, New Orleans, LA.
Sonia NapravnikSchool of Medicine, University of North Carolina, Chapel Hill, NC.
Katerina A ChristopoulosSchool of Medicine, University of California San Francisco, San Francisco, CA.
Bryan LauDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; School of Medicine, Johns Hopkins University, Baltimore, MD.
Geetanjali ChanderSchool of Medicine, Johns Hopkins University, Baltimore, MD; Department of Medicine, School of Medicine, University of Washington, Seattle, WA.
Johns Hopkins University · USUniversity of Washington · USJohns Hopkins Medicine · USHarvard University · USTulane University · USUniversity of California, San Diego · USUniversity of California, San Francisco · USUniversity of North Carolina at Chapel Hill · US

Funding

Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
North American AIDS Cohorts on Collaboration and Design (NAACCORD)U01AI069918 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Keri Nicole Althoff, RICHARD Douglas MOORE · 2006 to 2026
$65.2M
Johns Hopkins HIV Clinical CohortU01DA036935 · NIDA · JOHNS HOPKINS UNIVERSITY · PI MOORE, RICHARD DOUGLAS · 2014 to 2024
$14.9M
Alcohol Research Consortium in HIV: Relapse Prevention ArmP01AA029544 · NIAAA · JOHNS HOPKINS UNIVERSITY · PI HUTTON, HEIDI · 2021 to 2025
$7.1M
3/4 Alcohol Research Consortium in HIV - Epidemiological Research Arm (ARCH-ERA)U01AA020793 · NIAAA · UNIVERSITY OF WASHINGTON · PI CRANE, HEIDI M., LAU, BRYAN · 2011 to 2020
$5.8M
Ending the HIV Epidemic in Rural America (EHE-RA): Local Interventions, Co-Epidemics, and Social DeterminantsR01MD018539 · NIMHD · JOHNS HOPKINS UNIVERSITY · PI Anthony Todd Fojo · 2022 to 2026
$4.0M
1/4 Alcohol Research Consortium in HIV-Administrative Core (ARCH-AC)U24AA020801 · NIAAA · JOHNS HOPKINS UNIVERSITY · PI CHANDER, GEETANJALI, MCCAUL, MARY E · 2011 to 2021
$3.5M
Mentoring and Patient Oriented Research at the Nexus of Unhealthy Alcohol Use and HIVK24AA027483 · NIAAA · UNIVERSITY OF WASHINGTON · PI GEETANJALI CHANDER · 2019 to 2026
$1.3M
Optimizing outcomes at the intersection of HIV and mental health: Prediction, precision medicine, and population healthK08MH118094 · NIMH · JOHNS HOPKINS UNIVERSITY · PI FOJO, ANTHONY TODD · 2018 to 2022
$953k
The impact of social networks on hepatitis C transmission and care access in people who inject drugsK23DA041294 · NIDA · JOHNS HOPKINS UNIVERSITY · PI FALADE-NWULIA, OLUWASEUN · 2016 to 2020
$924k
Unhealthy alcohol use, other drug use, and mental health disorders: comorbidity burden in people with HIV, gaps in treatment, and impact on the HIV care continuumK01AA028193 · NIAAA · JOHNS HOPKINS UNIVERSITY · PI LESKO, CATHERINE · 2019 to 2023
$900k
NIAAA NIH HHS K01 AA028193NIAAA NIH HHS K24 AA027483NIAAA NIH HHS P01 AA029544NIAAA NIH HHS U01 AA020793NIAAA NIH HHS U24 AA020801NIAID NIH HHS P30 AI094189NIAID NIH HHS U01 AI069918NIDA NIH HHS K23 DA041294NIDA NIH HHS U01 DA036935NIMHD NIH HHS R01 MD018539NIMH NIH HHS K08 MH118094
6 · The paper itself

Abstract

purposeWe described the impact of alcohol use on longitudinal engagement in HIV care including loss to follow-up, durability of viral suppression, and death.

methodsWe followed a cohort of 1781 people with HIV from enrolled in care at one of seven US clinics, 2011-2019 through 102 months. We used a multistate, time-varying Markov process and restricted mean time to summarize engagement in HIV care over follow-up according to baseline self-reported alcohol use (none, moderate, or unhealthy).

resultsOur sample (86% male, 54% White) had median age of 35 years. Over 102 months, people with no, moderate, and unhealthy alcohol use averaged 62.3, 61.1, and 59.5 months virally suppressed, respectively. People who reported unhealthy or moderate alcohol use spent 5.1 (95% confidence intervals (CI): 0.8, 9.3) and 7.6 (95%CI: 3.1, 11.7) more months lost to care than nondrinkers. Compared to no use, unhealthy alcohol use was associated with 3.4 (95%CI: -5.6, -1.6) fewer months in care, not virally suppressed. There were no statistically significant differences after adjustment for demographic and clinical characteristics.

conclusionsModerate or unhealthy drinking at enrollment in HIV care was associated with poor retention in care. Alcohol use was not associated with time spent virally suppressed.

Indexed as

HIV InfectionsAdultContinuity of Patient CareFemaleHumansMaleViral LoadAlcohol useCompeting risksDescriptiveHIV careMultistate modelSurvivalViral suppression

Identifiers

PMID37442307
PMCPMC10538410
OpenAlexW4383896815

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.